JP2009510070A - 自己免疫及び神経変性疾患及び障害のためのエストリオール療法 - Google Patents

自己免疫及び神経変性疾患及び障害のためのエストリオール療法 Download PDF

Info

Publication number
JP2009510070A
JP2009510070A JP2008533482A JP2008533482A JP2009510070A JP 2009510070 A JP2009510070 A JP 2009510070A JP 2008533482 A JP2008533482 A JP 2008533482A JP 2008533482 A JP2008533482 A JP 2008533482A JP 2009510070 A JP2009510070 A JP 2009510070A
Authority
JP
Japan
Prior art keywords
treatment
disease
estriol
mice
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008533482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510070A5 (fr
Inventor
ヴォスクール，ロンダ・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2009510070A publication Critical patent/JP2009510070A/ja
Publication of JP2009510070A5 publication Critical patent/JP2009510070A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008533482A 2005-09-26 2006-09-26 自己免疫及び神経変性疾患及び障害のためのエストリオール療法 Pending JP2009510070A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72097105P 2005-09-26 2005-09-26
US83352706P 2006-07-26 2006-07-26
PCT/US2006/037259 WO2007038435A2 (fr) 2005-09-26 2006-09-26 Therapie par estriol pour maladies et troubles neurodegeneratifs et autoimmuns

Publications (2)

Publication Number Publication Date
JP2009510070A true JP2009510070A (ja) 2009-03-12
JP2009510070A5 JP2009510070A5 (fr) 2011-01-27

Family

ID=37900361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533482A Pending JP2009510070A (ja) 2005-09-26 2006-09-26 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Country Status (5)

Country Link
EP (1) EP1928468A4 (fr)
JP (1) JP2009510070A (fr)
AU (1) AU2006294826A1 (fr)
CA (1) CA2623905A1 (fr)
WO (1) WO2007038435A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050916A1 (fr) * 2008-10-31 2010-05-06 The Regents Of The University Of California Traitement avec un ligand de récepteur d’œstrogène pour des maladies neurodégénératives
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP2164498A4 (fr) 2007-06-04 2010-09-08 Univ California Association d'hormone de grossesse pour le traitement de maladies autoimmunes
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015168000A1 (fr) 2014-04-28 2015-11-05 The Regents Of The University Of California Combinaison d'oestrogènes pour le traitement de la sclérose en plaques
US10369158B2 (en) 2014-04-28 2019-08-06 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
EP3782616B1 (fr) 2014-09-02 2023-11-01 The Regents of The University of California Traitement par ligand du récepteur des estrogènes contre les maladies neurodégénératives
EP3188735A4 (fr) 2014-09-02 2018-01-24 The Regents of the University of California Thérapie oestrogénique pour traitement l'atrophie de la matière grise cérébrale et le handicap associé
US9962395B2 (en) 2014-09-29 2018-05-08 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
US10406169B2 (en) 2015-03-30 2019-09-10 The Regents Of The University Of California Methods of monitoring estriol therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514327A (ja) * 1993-11-05 1999-12-07 ユニバーシティ・オブ・フロリダ・リサーチ・ファウンデーション・インコーポレーテッド エストロゲン組成物及び神経保護の方法
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function
WO2002085374A1 (fr) * 2001-04-25 2002-10-31 The Regents Of The University Of California Therapie a base d'estriol pour le traitement de la sclerose en plaques et d'autres maladies auto-immunes
US20020164314A1 (en) * 2001-03-02 2002-11-07 Neurostasis, Inc. Ovarian hormone induced neural stem cell increase
JP2003246736A (ja) * 2002-02-25 2003-09-02 Noritake Co Ltd 自己免疫疾患発病抑制薬
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514327A (ja) * 1993-11-05 1999-12-07 ユニバーシティ・オブ・フロリダ・リサーチ・ファウンデーション・インコーポレーテッド エストロゲン組成物及び神経保護の方法
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function
US20020164314A1 (en) * 2001-03-02 2002-11-07 Neurostasis, Inc. Ovarian hormone induced neural stem cell increase
WO2002085374A1 (fr) * 2001-04-25 2002-10-31 The Regents Of The University Of California Therapie a base d'estriol pour le traitement de la sclerose en plaques et d'autres maladies auto-immunes
JP2003246736A (ja) * 2002-02-25 2003-09-02 Noritake Co Ltd 自己免疫疾患発病抑制薬
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN5007024041; ＫＩＭ　Ｓ: ＮＥＵＲＯＬＯＧＹ Ｖｏｌ．５２　Ｎｏ．１, 19990412, ｐｐ．１２３０-１２３８, ＬＩＰＰＩＮＣＯＴＴ　ＷＩＬＬＩＡＭＳ　＆　ＷＩＬＫＩＮＳ *
JPN5008015192; ＳＯＬＤＡＮ: ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＬＯＧＹ Ｖｏｌ．１７１　Ｎｏ．１１, 200312, ｐｐ．６２６７-６２７４ *
JPN5008015202; ＧＡＬＥＡ　ｅｔ　ａｌ．: ＢＥＨＡＶＩＯＵＲＡＬ　ＢＲＡＩＮ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．１２２　Ｎｏ．１, 2001, ｐｐ．１-９ *
JPN6012025511; Ｏｆｆｎｅｒ　Ｈ: 'Ｎｅｕｒｏｉｍｍｕｎｏｐｒｏｔｅｃｔｉｖｅ　ｅｆｆｅｃｔｓ　ｏｆ　ｅｓｔｒｏｇｅｎ　ａｎｄ　ｄｅｒｉｖａｔｉｖｅｓ　ｉｎ　ｅｘｐｅｒｉｍｅｎｔａｌ　ａｕｔｏｉｍｍｕｎｅ　ｅｎｃｅｐｈａｌｏｍｙｅｌｉｔ' Ｊ　Ｎｅｕｒｏｓｃｉ　Ｒｅｓ． Ｖｏｌ．７８　Ｎｏ．５, 20041201, ｐｐ．６０３-６２４ *
JPN6012025514; Ｃｏｎｆａｖｒｅｕｘ　Ｃ　ｅｔ　ａｌ．: 'Ｒａｔｅ　ｏｆ　ｐｒｅｇｎａｎｃｙ-ｒｅｌａｔｅｄ　ｒｅｌａｐｓｅ　ｉｎ　ｍｕｌｔｉｐｌｅ　ｓｃｌｅｒｏｓｉｓ．　Ｐｒｅｇｎａｎｃｙ　ｉｎ　Ｍｕｌｔｉｐｌｅ　Ｓｃｌｅｒｏｓｉｓ' Ｎ　Ｅｎｇｌ　Ｊ　Ｍｅｄ． Ｖｏｌ．３３９　Ｎｏ．５, 19980730, ｐｐ．２８５-２９１ *
JPN6012025516; Ｋｕｒｍａｎ　ＲＪ　ｅｔ　ａｌ．: 'Ｎｏｒｅｔｈｉｎｄｒｏｎｅ　ａｃｅｔａｔｅ　ａｎｄ　ｅｓｔｒａｄｉｏｌ-ｉｎｄｕｃｅｄ　ｅｎｄｏｍｅｔｒｉａｌ　ｈｙｐｅｒｐｌａｓｉａ．' Ｏｂｓｔｅｔ　Ｇｙｎｅｃｏｌ． Ｖｏｌ．９６　Ｎｏ．３, 200009, ｐｐ．３７３-３７９ *
JPN6012025519; メルクマニュアル日本語版 第１７版, 19991210, ｐｐ．１４７７-１４７９, 日経ＢＰ社 *
JPN6012025521; Ｋｕｉｐｅｒ　ＧＧ　ｅｔ　ａｌ．: 'Ｃｏｍｐａｒｉｓｏｎ　ｏｆ　ｔｈｅ　ｌｉｇａｎｄ　ｂｉｎｄｉｎｇ　ｓｐｅｃｉｆｉｃｉｔｙ　ａｎｄ　ｔｒａｎｓｃｒｉｐｔ　ｔｉｓｓｕｅ　ｄｉｓｔｒｉｂｕｔｉｏｎ　ｏｆ　ｅｓｔｒｏｇｅｎ　ｒｅｃｅｐｔｏｒ' Ｅｎｄｏｃｒｉｎｏｌｏｇｙ． Ｖｏｌ．１３８　Ｎｏ．３, 199703, ｐｐ．８６３-８７０ *
JPN6013005440; Ｈａｒｒｉｎｇｔｏｎ　ＷＲ　ｅｔ　ａｌ．: 'Ａｃｔｉｖｉｔｉｅｓ　ｏｆ　ｅｓｔｒｏｇｅｎ　ｒｅｃｅｐｔｏｒ　ａｌｐｈａ-　ａｎｄ　ｂｅｔａ-ｓｅｌｅｃｔｉｖｅ　ｌｉｇａｎｄｓ　ａｔ　ｄｉｖｅｒｓｅ　ｅｓｔｒｏｇｅｎ　ｒｅｓｐｏｎｓｉｖｅ　ｇｅｎ' Ｍｏｌ　Ｃｅｌｌ　Ｅｎｄｏｃｒｉｎｏｌ． Ｖｏｌ．２０６　Ｎｏ．１-２, 20030829, ｐｐ．１３-２２ *
JPN6013005441; Ｃａｒｓｗｅｌｌ　ＨＶ　ｅｔ　ａｌ．: 'Ｎｅｕｒｏｐｒｏｔｅｃｔｉｏｎ　ｂｙ　ａ　ｓｅｌｅｃｔｉｖｅ　ｅｓｔｒｏｇｅｎ　ｒｅｃｅｐｔｏｒ　ｂｅｔａ　ａｇｏｎｉｓｔ　ｉｎ　ａ　ｍｏｕｓｅ　ｍｏｄｅｌ　ｏｆ　ｇｌｏｂａｌ　ｉｓｃｈｅｍｉａ．' Ａｍ　Ｊ　Ｐｈｙｓｉｏｌ　Ｈｅａｒｔ　Ｃｉｒｃ　Ｐｈｙｓｉｏｌ． Ｖｏｌ．２８７　Ｎｏ．４, 20040520, ｐｐ．１５０１-１５０４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法

Also Published As

Publication number Publication date
WO2007038435A3 (fr) 2007-06-28
EP1928468A2 (fr) 2008-06-11
EP1928468A4 (fr) 2010-12-08
WO2007038435A2 (fr) 2007-04-05
AU2006294826A1 (en) 2007-04-05
CA2623905A1 (fr) 2007-04-05

Similar Documents

Publication Publication Date Title
JP2009510084A (ja) 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
US20090131385A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
JP2009510070A (ja) 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
US10610535B2 (en) Diarylpropionitrile therapy for treatment of multiple sclerosis
US9168262B2 (en) Estriol therapy for multiple sclerosis and other autoimmune diseases
US9452175B2 (en) Pregnancy hormone combination for treatment of autoimmune diseases
Sicotte et al. Treatment of multiple sclerosis with the pregnancy hormone estriol
US20210137943A1 (en) Estrogen combination for treatment of multiple sclerosis
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
WO2006053172A2 (fr) Estriol ou autres estranes, oestrogenes et compositions actives pour le recepteur d'oestrogenes utilises dans le traitement du psoriasis et d'autres maladies auto-immunes
US20120282222A9 (en) Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
US20090297477A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders
Harrison-Woolrych Breast and pelvic examination in women taking HRT.

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090928

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121024

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131029